Growing evidence shows that KRAS-mutation-driven cancer cells, including CRC, exhibit the metabolic vulnerability of being addicted to glutamine (Gln) (9–12), indicating that targeting Gln metabolism may be a promising therapeutic strategy for KRAS-mutation-driven cancers (13). The gene discussed is KRAS; the disease is colorectal carcinoma.